Tratamiento Exitoso para la Depresión Grave con Riesgo Suicida en un Paciente Trasplantado de Corazón

Q3 Medicine
María del Mar Arango-Posada, Ana Isabel Prada-Escobar, Carolina Marín-Hernández, Veronica Monsalve-Franco, Diana Restrepo-Bernal
{"title":"Tratamiento Exitoso para la Depresión Grave con Riesgo Suicida en un Paciente Trasplantado de Corazón","authors":"María del Mar Arango-Posada,&nbsp;Ana Isabel Prada-Escobar,&nbsp;Carolina Marín-Hernández,&nbsp;Veronica Monsalve-Franco,&nbsp;Diana Restrepo-Bernal","doi":"10.1016/j.rcp.2022.03.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Major depressive disorder is related to unfavourable outcomes in patients with severe comorbidities. In transplant patients, major depression is associated with worse clinical outcomes.</p></div><div><h3>Case report</h3><p>We present the case of a 55-year-old man with a heart transplant due to heart failure of ischaemic origin. Six months after the transplant he developed depressed mood, anhedonia and suicidal ideation with a score of 20/27 on the PHQ-9 depression screening scale. After receiving mirtazapine 30 mg/night for a week and persisting with a high suicide risk, it was decided to administer ketamine infusion for 24<!--> <!-->hours, with which a significant improvement in mood was observed, and the disappearance of suicidal ideation 24<!--> <!-->hours after the infusion.</p></div><div><h3>Discussion</h3><p>Depression in transplant patients is a factor associated with graft loss and post-transplant mortality, in addition to favouring other negative outcomes such as deep vein thrombosis.</p></div><div><h3>Conclusions</h3><p>Ketamine infusion was shown to be an effective and safe option to treat major depression with suicidal risk in a heart transplant patient.</p></div>","PeriodicalId":52477,"journal":{"name":"Revista Colombiana de Psiquiatria","volume":"53 2","pages":"Pages 210-216"},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Colombiana de Psiquiatria","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0034745022000269","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Major depressive disorder is related to unfavourable outcomes in patients with severe comorbidities. In transplant patients, major depression is associated with worse clinical outcomes.

Case report

We present the case of a 55-year-old man with a heart transplant due to heart failure of ischaemic origin. Six months after the transplant he developed depressed mood, anhedonia and suicidal ideation with a score of 20/27 on the PHQ-9 depression screening scale. After receiving mirtazapine 30 mg/night for a week and persisting with a high suicide risk, it was decided to administer ketamine infusion for 24 hours, with which a significant improvement in mood was observed, and the disappearance of suicidal ideation 24 hours after the infusion.

Discussion

Depression in transplant patients is a factor associated with graft loss and post-transplant mortality, in addition to favouring other negative outcomes such as deep vein thrombosis.

Conclusions

Ketamine infusion was shown to be an effective and safe option to treat major depression with suicidal risk in a heart transplant patient.

成功治疗心脏移植患者有自杀风险的严重抑郁症
导言重度抑郁症与患有严重并发症的患者的不良预后有关。本病例报告的患者是一名 55 岁的男性,因缺血性心力衰竭接受了心脏移植手术。移植六个月后,他出现了情绪低落、失神和自杀倾向,PHQ-9 抑郁症筛查量表评分为 20/27。在接受米氮平 30 毫克/晚的治疗一周后,自杀风险仍然很高,于是决定输注氯胺酮 24 小时,观察到情绪明显改善,输注 24 小时后自杀念头消失。结论氯胺酮输注被证明是治疗心脏移植患者有自杀风险的重度抑郁症的有效而安全的选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Revista Colombiana de Psiquiatria
Revista Colombiana de Psiquiatria Medicine-Psychiatry and Mental Health
CiteScore
2.50
自引率
0.00%
发文量
72
期刊介绍: Revista Colombiana de Psiquiatría (RCP) is a quarterly official publication of Colombian Psychiatry Association (March, June, September and December) and its purpose is to spread different the knowledge models that currently constitute the theoretical and practical body of our specialty. Psychiatrists, psychiatric residents, non psychiatric physicians, psychologists, philosophers or other health professionals or persons interested in this area can take part in the magazine. This journal publishes original works, revision or updating articles, case reports of all psychiatry and mental health areas, epistemology, mind philosophy, bioethics and also articles about methodology of investigation and critical reading.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信